Friday, October 9, 2015: 10:30 AM-12:00 PM
Room: 6--CF
Learning Objectives:
At the conclusion of this session, participants will be able to:
- discuss the clinical impact of emerging mechanisms of resistance to selected pathogens using real clinical cases
- examine the mechanistic basis for antibiotic choices in resistant bacterial and fungal pathogens
- assess the consequences of emerging resistance on patient outcome
Target Audience: Scientists, Researchers, Pharmacists, Microbiologists, Members-in-training, Lab personnel, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Healthcare workers, Fellows, Epidemiologists, Clinicians, Academicians
Tracks: Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID, Trainee
Moderators:
Cesar Arias, MD, PhD, FIDSA, University of Texas Medical School at Houston
and
Maria Virginia Villegas, MD, MSc, FIDSA, Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM)
Presentations:
CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM
ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE
ACPE Number: 0221-9999-15-175-L01-P
Disclosures:
C. Arias,
Pfizer:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Merck Sharp and Dohme:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Cubist:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Theravance:
Grant Investigator
and
Speaker's Bureau
,
Grant recipient
and
Speaker honorarium
Bayer:
Consultant
,
Consulting fee
See more of: Symposium